Zimmer Biomet Holdings, Inc. $ZBH is Oak Family Advisors LLC’s 10th Largest Position

Oak Family Advisors LLC reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 84,323 shares of the medical equipment provider’s stock after selling 18,735 shares during the period. Zimmer Biomet accounts for about 2.1% of Oak Family Advisors LLC’s portfolio, making the stock its 10th largest position. Oak Family Advisors LLC’s holdings in Zimmer Biomet were worth $8,306,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after acquiring an additional 198,370 shares in the last quarter. Dodge & Cox boosted its position in shares of Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after purchasing an additional 2,533,009 shares in the last quarter. American Century Companies Inc. grew its stake in Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after buying an additional 458,903 shares during the last quarter. Geode Capital Management LLC increased its position in Zimmer Biomet by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares in the last quarter. Finally, Primecap Management Co. CA raised its stake in Zimmer Biomet by 0.6% in the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after buying an additional 27,860 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.5%

ZBH stock opened at $94.07 on Friday. The company has a market capitalization of $18.64 billion, a P/E ratio of 23.28, a price-to-earnings-growth ratio of 2.36 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a 12 month low of $85.33 and a 12 month high of $114.44. The firm’s fifty day simple moving average is $92.20 and its 200-day simple moving average is $96.55. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup dropped their price target on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research report on Thursday, September 18th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $107.75.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.